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Objective. It is generally recognized that the immune system has an important role in regulating cancer
development. Evidence indicating a prognostic role of the immune system in vulvar carcinoma is scarce.
This study investigated the presence and prognostic signiﬁcance of several aspects of the immune system
in vulvar squamous carcinoma.
Methods. The number of intratumoral CD8+ and Foxp3+ T-lymphocytes, next to HLA class I (HLA-A, HLA-B/C
and β2-m) and indoleamine 2,3-dioxygenase (IDO) expression was determined by immunohistochemistry in a
consecutively selected cohort of 286 vulvar squamous carcinoma patients, all treated in the University Medical
Center Groningen, the Netherlands. Associations between immunohistochemistry expression and the inﬂuence
on survival were determined.Results. The number of tumor-inﬁltrating CD8+ T-lymphocytes was signiﬁcantly lower in tumors with loss
of HLA-A (p=0.004), HLA-B/C (p=0.024) or β2-m (p=0.025) expression comparedwith tumors with expres-
sion of HLA class I. No association was found between the number of intratumoral CD8+ T-lymphocytes and
Foxp3+ T-lymphocytes, HLA class I and IDO expression and survival of vulvar squamous carcinoma patients.
Conclusion. Our results indicate that the immune systemdoes not seem to have amajor inﬂuence on prognosis
of patients with vulvar squamous carcinoma.© 2011 Elsevier Inc. All rights reserved.Introduction
Vulvar carcinoma is a rare disease accounting for only 5% of all gyne-
cological malignancies [1]. Mainly elderly women are affected with a
peak incidence in the eight decade [2]. Squamous cell carcinoma is the
most common histological subtype and occurs in 90% of all vulvar carci-
nomas [3,4]. Stage, tumor size, depth of invasion, vascular space invasion
and especially lymph node metastases are important prognostic factors
[3]. The 5-year survival is generally good for FIGO stage I (79%) but de-
clines with more advanced stage of disease: stage II (59%), stage III
(43%) and stage IV (13%) [2]. Surgery is the cornerstone of vulvar carcino-
ma treatment and consists of a wide local excision with uni- or bilateral
inguinofemoral lymphadenectomy via separate incisions. An important
improvement in vulvar cancer treatmentwas the introduction of sentinel
node dissection in selected patientswith early stage disease [5]. Adjuvant
radiotherapy is indicated in patients with lymph node metastases [6],
and chemoradiation is a possibility for (locally) advanced vulvar carcino-
ma [7]..
rights reserved.Despite developments during the last years, improvement of
treatment and prognosis of vulvar carcinoma patients is still needed.
In this respect, immunotherapy might be an interesting new treat-
ment option where it is generally recognized that the immune system
has an important role in regulating cancer development [8].
Cytotoxic T-lymphocytes (CTL) are important effector cells in the
adaptive immune system, able to recognize cancer cells as “non-self”
and subsequently kill them. Recognition of “non-self” by CTLs can only
take place when antigenic peptides (which are derived from digested
proteins and broken down in the proteasome of the cell and transported
to the cell surface) are presented by the human leukocyte antigen (HLA)
class I present at the cell surface of every nucleated cell. The importance
of CTL as part of anti-tumor responsewas emphasized by studies in sev-
eral cancers demonstrating an association between a high number of
tumor-inﬁltrating CD8+ T-lymphocytes (CTL) and increased survival
[9–14].
However, cancer cells can develop several strategies to escape
eradication by the immune system [15]. Downregulation of the HLA
class I molecule is one such powerful mechanism, preventing immune
recognition and lysis by CTLs. Another mechanism is the induction of
regulatory T-lymphocytes (Tregs) which are known for their immuno-
suppressive function. Increasing evidence shows that Tregs play amajor
187R.A. de Jong et al. / Gynecologic Oncology 125 (2012) 186–193role in modulating host response to tumors; by suppressing effector
T-lymphocyte proliferation (i.e. CTL) an adequate tumor-speciﬁc im-
mune response is prohibited. Increased numbers of intratumoral Tregs
was associated with impaired prognosis in several malignancies
[16–20]. Furthermore, the intracellular enzyme indoleamine 2,3-
dioxygenase (IDO) is currently considered an important immune es-
cape mechanisms in cancer. IDO catalyses the ﬁrst and rate-limiting
steps in the breakdown of the essential amino acid tryptophan along
the kynurenine pathway where several downstreammetabolites are
formed [21]. IDO expression can occur in several cell types (e.g. den-
dritic cells or cancer cells) after induction by IFN-γ or lipopolysac-
charide. IDO exerts its immunosuppressive function by suppressing
effector T-lymphocytes and natural killer (NK) cells. Our group re-
cently showed that IDO activity is signiﬁcantly increased in serum
of patients with endometrial, ovarian and vulvar cancer compared
to healthy controls [22].
In vulvar carcinoma, evidence for the (prognostic) role of the immune
system in vulvar carcinoma is scarce [23,24] and research iswarranted on
this subject. Therefore, this study aimed to determine the prognostic role
of several aspects of the immune system in vulvar carcinoma patients.
Therefore, the presence and prognostic inﬂuence of two important sub-
sets of T-lymphocytes (CD8+ and Foxp3+ T-lymphocytes), next to HLA
class I downregulation and IDO expression were determined in a large
and consecutively selected cohort of patients with vulvar carcinoma.
Materials and methods
Patients
Tissue samples of all patients with gynecological malignancies
treated at the Department of Gynecological Oncology of the Universi-
ty Medical Center Groningen (UMCG) are prospectively collected and
stored in the tissue storage system of the Department of Pathology of
the UMCG, the Netherlands. Clinicopathological characteristics and
follow-up data of all these patients are prospectively collected during
standard treatment and follow-up and stored in a computerized reg-
istration database. For the present study, tissue material and data of
clinicopathological characteristics of patients with vulvar carcinoma
were used as reported previously [25]. Patients had been consecutively
selected when treated for squamous cell carcinoma of the vulva in the
UMCG between 1984 and 2001. Patients were excluded when treated
with a histological subtype other than squamous cell carcinoma or if
they had been treated with preoperative radiotherapy. Staging was per-
formed according to the surgicopathological FIGO classiﬁcations applica-
ble at that time [26] and the AJCC TNM classiﬁcation [27]. Follow-up data
were updated until July 2010.
Institutional review board approval
All relevant datawere retrieved fromour computerized database into
a separate, anonymous, password protected database. Patient identity
was protected by study speciﬁc, unique patient codes, which were only
known to two dedicated data managers, who also have responsibility
for the larger database. In case of uncertainties with respect to clinico-
pathological and follow-up data, the larger databases could only be
checked through the datamanagers, thereby ascertaining the protection
of patients’ identity. Due to these procedures, according to Dutch law no
further patient or institutional review board approval was needed.
Immunohistochemistry
For staining, 4-μm sections were cut from previously constructed
tissue microarrays of formalin-ﬁxed parafﬁn-embedded tumors [25]
and applied to 3-amino-propyl-triethoxy-silane coated glass slides
(Sigma-Aldrich, Diesenhofen, Germany). For immunostaining, tissue
microarray slides were ﬁrst dewaxed and rehydrated. Methods andantibodies for immunostaining of CD8+ T-lymphocytes, Foxp3+
T-lymphocytes, HLA-B/C and β2m were used as previously reported
[22,28]. For HLA-A and IDO, antigen retrieval was performed by mi-
crowave treatment; 15 min in citrate (pH 6.0) (HLA-A), and EDTA
buffer (pH 8.0) (IDO). Endogenous peroxidase activity was blocked
with 0.3% H2O2 for 30 min after which the slides were incubated
with the primary antibodies for 60 min at room temperature (dilu-
tions 1:100); HCA2 recognizing the HLA class I heavy chain HLA-A
(kindly provided by Prof., Dr. J.J. Neefjes, The Netherlands Cancer In-
stitute, Amsterdam, The Netherlands), and a mouse monoclonal anti-
body recognizing IDO (anti-indoleamine 2,3-dioxygenase, clone 10.1;
Millipore (Chemicon)) were used. Sections were incubated with
RAMpo (rabbit anti-mouse peroxidase-labeled) and GARpo (goat anti-
rabbit peroxidase-labeled) (DAKO, Heverlee, Belgium, 1:100). Antigen–
antibody reactions were visualized with 3,3-diaminobenzidine and sec-
tions were counterstained with haematoxylin.
Evaluation of immunohistochemistry staining
Immunohistochemistry stained slides were scored independently
by two investigators (RJ and NT) when at least 2 cores per case were
present, each containing at least 20% tumor tissue. The number of pos-
itively stained intratumoral CD8+ and Foxp3+ T-lymphocytes was
counted and the average number was calculated per 0.283 mm2 of
tumor (i.e. one whole core consisting of 100% tumor tissue) (Figs. 1A
and B) [9,10].
IDO expression was assessed according to a semi-quantitative scale
which is based on the extent and intensity of the staining [29]. Intensity
of the cytoplasmic staining was scored as 0 for absent, 1 for weak, 2 for
positive or 3 for strong positive expression. The percentage was scored
as 0 for 0–5%; 1 for ≥5–30%; 2 for ≥30–70% and 3 for ≥70–100%. The
sum of scores was used to identify four categories of expression: IDO–
(sum: 0–1), IDO1+ (sum: 2–3), IDO2+ (sum: 4–5) and IDO3+ (sum: 6)
(Figs. 1C and 1D). Mean result of the cores was considered as deﬁnitive
IDO expression.
A semiquantitative scoring systemwas also used for HC-10, HC-A2
and β2-m expression. Intensity of the membrane staining was scored
as 0 for absent; 1 for weak; 2 for positive or 3 for strong positive ex-
pression. The percentage was scored as 0 for 0%; 1 for ≥1–5%; 2 for
≥5–25%; 3 for ≥25–50%; 4 for ≥50–75% and 5 for ≥75–100%. The
sum of both scores was used to identify three categories of expression:
normal expression (6.5–8), partial loss (2.5–6.5) and total loss (0–2.5)
(Figs. 1E–M). Mean result of the cores was considered as deﬁnitive
HC-10, HC-A2 and β2-m expression.
Statistical analysis
All continuous variableswere tested for normality. In case of skewed
distributions, the median and interquartile ranges (IQR, 25th to 75th
percentile) were presented. Staining of HLA class I was dichotomized;
partial loss and normal expression were taken together and compared
to total loss of expression. Associations between clinicopathological
characteristics (see Table 1) and the number of CD8+ T-lymphocytes,
Foxp3+ T-lymphocytes (dichotomized according to their median),
IDO, HLA-A, HLA-B/C and β2-m expression was estimated using univar-
iate logistic regression analyses. Clinicopathological parameters were
used as independent and T-lymphocytes, IDO expression and HLA
class I components were used as dependent variables. Odds Ratios
(ORs) and 95%-conﬁdence intervals (95%-CI) were estimated. Univariate
and multivariate Cox proportional hazard analysis were used to assess
inﬂuence of clinicopathological characteristics, numbers of CD8+
T-lymphocytes and Foxp3+ T-lymphocytes and expression levels of
IDO, HLA-A, HLA-B/C and β2-m on survival. Disease-free survival (DFS)
was deﬁned as date of diagnosis until recurrent disease, metastasis,
death due to vulvar cancer or last date of follow-up. Disease speciﬁc sur-
vival (DSS) was deﬁned as date of diagnosis until death due to vulvar
Fig. 1. Immunohistochemistry staining of intratumoral CD8+ T-lymphocytes (A) and Foxp3+ T-lymphocytes (B), IDO expression ; negative (C), positive (D) and HLA class I heavy
chain HCA2 (E–G), HC10 (H–J) and β2-m (K–M) (loss of expression: E,H,K; partial loss: F, I, L; normal expression: G, J, M).
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Table 1
Clinicopathological characteristics of 286 patients with vulvar carcinoma.
Patients (n=286) (%)a
Age (years)







T1 (maximum diameter ≤2 cm) 74 (25.9)
T2 (maximum diameter >2 cm) 212 (74.1)
Missing 0
Inﬁltration depth
≤5 mm 116 (41.3)











No metastasis 157 (59.9)












a Percentages exclude missing cases.
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tics and immunohistochemistry expression were used as independent
and recurrent disease (DFS) or death of disease (DSS) were used as de-
pendent variables. Hazard Ratios (HRs) and 95%-CIs were calculated.
Variables with a p value b0.05 in univariate analysis were simultaneous-
ly entered into the multivariate model. All tests were performed two-
sided and p values of b0.05 were considered statistically signiﬁcant.




In total, 286 patients with vulvar carcinoma were included in this
study of whom clinicopathological characteristics are depicted in
Table 1. Median age at time of diagnosis was 73 years (IQR:
63–81 years). The majority of the patients were diagnosed with a T2
tumor (74.1%). The tumor was localized unilateral in 84.3% and multifo-
cality was observed in 15.7%. One or more inguinofemoral metastasis
were present in 40.1% of the patients whereas 59.9% did not show ingui-
nofemoral metastasis.Associations between clinicopathological characteristics and immunological
factors
CD8+ and Foxp3+ T-lymphocytes
Intratumoral CD8+ and Foxp3+ T-lymphocytes were present in
96.3% (median 36; IQR 14–93) and 95.1% (median 17; IQR 7–42). The
median CD8+/Foxp3+ ratio was 1.73 (IQR 0.97–3.86). Tumors with in-
ﬁltration depth of >5 mmwere associatedwith a high number of CD8+
T-lymphocytes and a high CD8+/Foxp3+ ratio (Table 2). A T2 tumor
more frequently had a high CD8+/Foxp3+ T-lymphocytes ratio. No
associations were found between clinicopathological characteristics
and the number of Foxp3+ T-lymphocytes.
HLA class I downregulation
Downregulation of HLA-A, HLA-B/C or β2-m was observed in 37.9%,
11.1% and 2.2%, respectively. Age and positive vascular invasion were
associated with HLA-A downregulation and poorly differentiated tu-
mors were associated with HLA-B/C downregulation (Table 3). A low
number of CD8+ T-lymphocytes was associated with downregulation
of HLA-A, HLA-B/C and β2-m. Furthermore, a high number of Foxp3+
T-lymphocytes was associated with downregulation of HLA-A, HLA-B/
C and β2-m.
IDO expression
IDO expressionwas present in 50.4% of the cases. As shown bymeans
of univariate logistic regression analysis (Table 3), no associations were
found between clinicopathological characteristics, HLA class I downregu-
lation, the number of T-lymphocytes and IDO expression.
Survival
Median time of follow-up was 73 months (IQR: 0–290 months). In
98 patients (32.6%), recurrence of diseasewas diagnosedwith amedian
time until recurrence of 23 months (IQR: 7.0–65.0 months). In total, 76
patients (25.5%) died as a result of vulvar carcinoma during our follow-
up.
In univariate analyses on DFS, only the presence of inguinofemoral
metastasis was signiﬁcantly related to a shorter DFS (Table 4).
In univariate analyses on DSS, inguinofemoral metastasis, T2
tumor, a high tumor grade, positive vascular invasion and inﬁltration
depth >5 mm were predictors for a worse DSS, in order of impor-
tance (Table 5). In multivariate analysis, inguinofemoral metastasis,
T2 tumor, a high tumor grade and positive vascular invasion were in-
dependent predictors for a shorter DSS.
The number of CD8+ T-lymphocytes and Foxp3+ T-lymphocytes,
HLA class I downregulation, IDO expression were not related to DSS.
Discussion
In this large and well-documented cohort of 286 patients with
vulvar carcinoma, we evaluated the prognostic signiﬁcance of several
aspects of the immune system. We showed that the number of CD8+
T-lymphocytes was signiﬁcantly related to HLA class I downregula-
tion which reﬂects the natural mechanism of this interaction. Howev-
er, the number of intratumoral CD8+ T-lymphocytes or Foxp3+ T-
lymphocytes, HLA class I downregulation and IDO expression were
not associated with survival. Our results indicate that the immune
system does not seem to have a major inﬂuence on prognosis of pa-
tients with vulvar carcinoma.
The prognostic inﬂuence of tumor-inﬁltrating T-lymphocytes and
more speciﬁcally, CD8+ and Foxp3+ T-lymphocytes has been studied
in several cancer types. In this cohort of 286 vulvar carcinoma pa-
tients, intra-tumoral CD8+ and Foxp3+ T-lymphocytes were present
in 96.3% and 95.1% of the cases. In agreement with results of a recently
published study in vulvar carcinoma [23], we did not ﬁnd an associa-
tion between the number of T-lymphocytes and survival of vulvar
Table 2
Association between CD8+ T-lymphocytes, Foxp3+ T-lymphocytes, CD8+/Foxp3+ ratio and clinicopathological factors in 286 vulvar carcinoma patients.
CD8+T-lymphocytes Low CD8+T-lymphocytes
bMedian ≥Median OR (95% CI) p value
Age 1.00 (0.98-1.02) 0.831
Tumor grade 3/undifferentiated 16/104 (15.4%) 14/114 (12.2%) 1.30 (0.60-2.81) 0.507
T-status: T2 (max. diameter >2 cm) 75/105 (71.4%) 84/114 (73.7%) 0.89 (0.49-1.62) 0.709
Inﬁltration depth>5 mm 53/102 (52.0%) 74/113 (65.5%) 0.57 (0.33-0.99) 0.045
Vascular invasion positive 17/102 (16.7%) 18/103 (17.5%) 0.94 (0.46-1.96) 0.878
Multifocality 14/105 (13.3%) 24/114 (21.1%) 0.58 (0.28-1.19) 0.135
Inguinofemoral metastasis 35/94 (37.2%) 44/106 (41.5%) 0.84 (0.47-1.48) 0.537
Foxp3+ T-lymphocytes High Foxp3+ T-lymphocytes
bMedian ≥Median OR (95% CI) p value
Age 0.99 (0.97–1.01) 0.440
Tumor grade 3/undifferentiated 13/99 (13.1%) 20/123 (16.3%) 1.29 (0.60–2.73) 0.515
T-status: T2 (max. diameter >2 cm) 78/100 (78.0%) 84/123 (68.3%) 0.61 (0.33–1.11) 0.107
Inﬁltration depth>5 mm 58/96 (60.4%) 72/123 (58.5%) 0.93 (0.54–1.59) 0.779
Vascular invasion positive 12/89 (13.5%) 24/119 (20.2%) 1.62 (0.76–3.45) 0.210
Multifocality 14/100 (14.0%) 25/123 (20.3%) 1.57 (0.77–3.21) 0.219
Inguinofemoral metastasis 33/89 (37.1%) 49/114 (43.0%) 1.28 (0.73–2.26) 0.395
CD8+/Foxp3+ ratio Low CD8+/Foxp3+ ratio
bMedian ≥Median OR (95% CI) p value
Age 1.00 (0.98-1.02) 0.715
Tumor grade 3/undifferentiated 16/106 (13.8%) 14/107 (13.1%) 1.18 (0.55-2.56) 0.673
T-status: T2 (max. diameter >2 cm) 70/107 (65.4%) 86/107 (80.4%) 0.46 (0.25-0.86) 0.015
Inﬁltration depth>5 mm 53/105 (50.5%) 73/105 (69.5%) 0.45 (0.25-0.79) 0.005
Vascular invasion positive 22/105 (21.0%) 13/95 (13.7%) 1.67 (0.79-3.54) 0.180
Multifocality 20/107 (18.7%) 17/107 (15.9%) 1.22 (0.60-2.48) 0.588
Inguinofemoral metastasis 37/95 (38.9%) 41/100 (41.0%) 0.92 (0.52-1.63) 0.770
Bold values signify pb0.05.
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performed in endometrial [9,11], ovarian [10,30] and cervical carcino-
ma [31].
In this study, vulvar carcinomas with inﬁltration depth of >5 mm
were associated with a high number of CD8+ T-lymphocytes and a
high CD8+/Foxp3+ ratio. Furthermore, a T2 tumor more frequently
had a high CD8+/Foxp3+ T-lymphocytes ratio. These results are in
contrast to results found in other cancer types where high numbers
of CD8+ and low numbers of Foxp3+ T-lymphocytes were associated
with favourable outcome [9–12,32]. The fact that larger tumors are
associated with inﬁltration with more T-lymphocytes suggests that
inﬁltration did not result in effective eradication of the tumor. A pos-
sible cause might be the simultaneous downregulation of HLA class I,
which prevents recognition and lysis of the cancer cells by CD8+ T-
lymphocytes. This hypothesis is supported by results of univariate lo-
gistic regression analyses; the number of tumor-inﬁltrating CD8+ T-
lymphocytes was signiﬁcantly lower in tumors with downregulation
of HLA class I (either loss of HLA-A, HLA-B/C or β2-m expression)
compared with tumors with expression of HLA class I.
Younger patients with vulvar carcinoma more frequently showed
downregulation of HLA-A. Furthermore, positive vascular invasion
was associated with HLA-A downregulation, and poorly differentiated
tumors were associated with HLA-B/C downregulation. These results
suggest an association between poor prognostic factors and downre-
gulation of HLA class I. However, HLA class I downregulation did not
have a signiﬁcant inﬂuence on survival of patients with vulvar carcino-
ma. These results are in contrast to studies in endometrial [28], ovarian
[33,34] and cervical cancer [31,35] where an association between
downregulation of HLA class I and poor prognosis was observed.
IDO is currently considered an important immune escape mecha-
nism in cancer. We have recently shown that IDO activity is signiﬁ-
cantly increased in serum of patients with vulvar cancer [22],
suggesting that IDO also plays a role in vulvar carcinoma. IDO expres-
sion has been associated with decreased prognosis in several cancertypes In contrast to results of a recent study in 76 vulvar carcinoma
patients [24], we did not ﬁnd an association between IDO expression
and clinicopathological characteristics or survival. The intracellular
enzyme IDO functions as an immune escape mechanism by means
of suppressing T-lymphocytes and NK cells and therefore we
expected an inverse relation between the number of CD8+ T-
lymphocytes and IDO expression. However, we did not observe such
a relation. These results suggest that the immune system has a differ-
ent function in vulvar carcinoma compared to other gynecological
malignancies such as endometrial, ovarian and cervical cancer. Possi-
bly, the fact that vulvar carcinoma is localized on the skin might cause
these differences. One other explanation might be the fact that pa-
tients diagnosed with vulvar carcinoma are generally older compared
to patients diagnosed with endometrial, ovarian or cervical cancer.
Aging is associated with a change in immune activation, especially
of the T-cell/macrophage system. Due to an IFN-γ dependent increase
of IDO activity amongst elderly, infections, autoimmune diseases and
malignancies occur more often [36].
The presence of inguinofemoral metastasis was the only factor
which signiﬁcantly related to a shorter DFS. Furthermore, the pres-
ence of inguinofemoral metastasis was an independent predictor for
a worse DSS, next to a T2 tumor, poorly/undifferentiated differentiat-
ed tumor and positive vascular invasion. These results are in agree-
ment with previous studies determining the prognostic role of
several surgicopathological characteristics in patients with vulvar
carcinoma [3].
This study evaluated the presence and prognostic inﬂuence of im-
portant players in cellular immunity and to our knowledge, we are
the ﬁrst to evaluate HLA class I downregulation in vulvar carcinoma.
We were able to evaluate immunohistochemistry expression on tis-
sue material of a unique large number (n=286) of vulvar carcinoma
patients, all treated with primary surgery in a single institution
(UMCG, Groningen, the Netherlands). In order to evaluate this large
series of specimens in a high-throughput manner, we used a
Table 3
Association between clinicopathological characteristics and HLA class I downregulation and IDO expression in 286 vulvar cancer patients.
HLA-A HLA-A downregulation
Loss of expression (n=86) Expression (n=141) OR (95% CI) p value
Age 0.98 (0.96–1.00) 0.027
Tumor grade 3/undifferentiated 15/86 (17.4%) 19/140 (13.6%) 1.35 (0.64–2.81) 0.430
T-status: T2 (max. diameter >2 cm) 65/86 (75.6%) 101/141 (71.6%) 1.23 (0.66–2.26) 0.515
Inﬁltration depth>5 mm 35/85 (41.2%) 78/138 (56.5%) 1.27 (0.73–2.22) 0.391
Vascular invasion positive 20/82 (24.4%) 17/130 (13.1%) 2.14 (1.05–4.39) 0.037
Multifocality 11/86 (12.8%) 30/141 (21.3%) 0.54 (0.26–1.15) 0.110
Inguinofemoral metastasis 35/78 (44.9%) 48/131 (36.6%) 1.41 (0.80–2.49) 0.240
IDO expression 45/84 (53.6%) 66/133 (49.6%) 1.17 (0.68–2.02) 0.571
CD8+ T-lymphocytes 1.00 (0.99–1.00) 0.080
CD8+ T-lymphocytesbmedian 52/85 (61.2%) 53/129 (41.1%) 2.26 (1.29–3.96) 0.004
Foxp3+ T-lymphocytes 0.98 (0.97–0.99) 0.002
Foxp3+ T-lymphocytes ≥ median 33/84 (39.3%) 85/133 (63.9%) 2.74 (1.56–4.81) b0.001
CD8+/Foxp3+ ratio 1.01 (0.99–1.02) 0.373
HLA-B/C HLA-B/C downregulation
Loss of expression (n=25) Expression (n=201) OR (95% CI) p value
Age 1.01 (0.98–1.05) 0.490
Tumor grade 3/undifferentiated 9/27 (33.3%) 23/200 (11.5%) 4.33 (1.72–10.92) 0.002
T-status: T2 (max. diameter >2 cm) 20/27 (74.1%) 148/201 (73.6%) 0.92 (0.36–2.33) 0.862
Inﬁltration depth>5 mm 20/27 (74.1%) 114/197 (57.9%) 1.87 (0.75–4.69) 0.180
Vascular invasion positive 7/26 (26.9%) 30/187 (16.0%) 2.16 (0.82–5.65) 0.118
Multifocality 4/27 (14.8%) 37/201 (18.4%) 0.84 (0.27–2.61) 0.768
Inguinofemoral metastasis 11/23 (47.8%) 71/184 (38.6%) 1.33 (0.55–3.23) 0.534
IDO expression 15/25 (60.0%) 96/194 (49.5%) 1.91 (0.78–4.72) 0.159
CD8+ T-lymphocytes 0.99 (0.99–1.00) 0.159
CD8+ T-lymphocytesbmedian 17/25 (68.0%) 86/189 (45.5%) 2.91 (1.13–7.34) 0.024
Foxp3+ T-lymphocytes 0.94 (0.91–0.98) 0.002
Foxp3+ T-lymphocytes≥median 4/25 (16.0%) 115/193 (59.6%) 0.14 (0.05–0.41) b0.001
CD8+/Foxp3+ ratio 1.00 (0.99–1.02) 0.613
β2-m β2-m downregulation
Loss of expression (n=5) Expression (n=221) OR (95% CI) p valuea
Age 0.663
Tumor grade 3/undifferentiated 0/5 (0%) 34/220 (15.5%) n.a. 0.340
T-status: T2 (max. diameter >2 cm) 5/5 (100%) 162/221 (73.3%) n.a. 0.330
Inﬁltration depth>5 mm 3/5 (60%) 127/216 (58.8%) n.a. 0.957
Vascular invasion positive 1/5 (20.0%) 35/205 (17.1%) n.a. 0.864
Multifocality 1/5 (20.0%) 40/221 (18.1%) n.a. 0.913
Inguinofemoral metastasis 3/5 (60.0%) 81/203 (39.9%) n.a. 0.366
IDO expression 2/4 (40.0%) 110/213 (51.6%) n.a. 0.330
CD8+ T-lymphocytes n.a. n.a.
CD8+ T-lymphocytesbmedian 5/5 (100%) 98/208 (47.1%) n.a. 0.025
Foxp3+ T-lymphocytes n.a. n.a.
Foxp3+ T-lymphocytes≥median 0/5 (0%) 118/212 (55.7%) n.a. 0.019
CD8+/Foxp3+ ratio n.a. 0.650
IDO IDO high expression
Negative Positive OR (95% CI) p value
Age 1.01 (0.99–1.03) 0.341
Tumor grade 3/undifferentiated 12/116 (10.3%) 20/120 (16.7%) 1.65 (0.76–3.58) 0.206
T-status: T2 (max. diameter >2 cm) 87/117 (74.4%) 87/120 (72.5%) 0.90 (0.50–1.61) 0.717
Inﬁltration depth>5 mm 69/113 (61.1%) 70/118 (59.3%) 0.90 (0.53–1.54) 0.707
Vascular invasion positive 16/109 (14.7%) 23/109 (21.1%) 1.44 (0.70–3.00) 0.325
Multifocality 19/117 (16.2%) 20/120 (16.7%) 0.98 (0.49–1.97) 0.953
Inguinofemoral metastasis 39/103 (37.9%) 46/110 (41.8%) 1.21 (0.69–2.11) 0.507
HLA-A downregulation 42/110 (38.2%) 45/115 (39.1%) 1.17 (0.68–2.02) 0.571
HLA-B/C downregulation 10/110 (9.1%) 15/116 (12.9%) 1.91 (0.78–4.72) 0.159
β2-m downregulation 2/109 (1.8%) 2/116 (1.7%) 0.94 (0.13–6.77) 0.948
CD8+ T-lymphocytes 1.00 (1.00–1.00) 0.936
CD8+ T-lymphocytesbmedian 54/110 (49.1%) 56/116 (48.3%) 0.93 (0.55–1.59) 0.796
Foxp3+ T-lymphocytes 1.00 (0.99–1.01) 0.758
Foxp3+ T-lymphocytes≥median 58/109 (53.2%) 65/116 (56.0%) 1.17 (0.69–1.99) 0.565
CD8+/Foxp3+ ratio 1.01 (0.99–1.02) 0.389
FIGO=International Federation of Gynecology and Obstetrics.
n.a. = not applicable.
a Statistical analysis by Pearson's Chi-square.
191R.A. de Jong et al. / Gynecologic Oncology 125 (2012) 186–193previously constructed tissue microarray [25]. This method is widely
used in cancer research and was recently validated for vulvar carcino-
ma [37]. Our results showed that none of these immunologicalparameters have a signiﬁcant inﬂuence on survival of vulvar carcinoma
patients, in contrast to results of studies in several other cancer types.
However, as there is a relationship between effect and study size, we
Table 4
COX regression analysis on disease free survival.
Univariate analysis Multivariate
analysis
HR 95% CI p value
Age 1.01 1.00–1.03 0.126 a
Tumor grade 3/undifferentiated 1.42 0.83–2.43 0.203 a
T-status: T2 (max. diameter >2 cm) 1.38 0.87–2.19 0.171 a
Inﬁltration depth>5 mm 1.30 0.86–1.95 0.217 a
Vascular invasion positive 1.60 0.94–2.72 0.082 a
Multifocality 1.48 0.90–2.42 0.119 a
Inguinofemoral metastasis 2.23 1.48–3.36 b0.001 a
IDO expression 1.24 0.79–1.93 0.348 a
HLA-A downregulation 0.95 0.59–1.51 0.813 a
HLA-B/C downregulation 0.76 0.33–1.76 0.526 a
β2-m downregulation 0.55 0.08–3.94 0.550 a
CD8+ T-lymphocytes 1.00 0.99–1.00 0.067 a
Foxp3+ T-lymphocytes 1.00 0.99–1.01 0.899 a
CD8+/ Foxp3+ ratio 1.00 0.98–1.01 0.438 a
Bold values signify pb0.05.
a Not included in multivariate analysis.
Table 5
COX regression analysis on disease speciﬁc survival.
Univariate analysis Multivariate analysis
HR 95% CI p value HR 95% CI p value
Age 1.01 1.00–1.03 0.235 a
Tumor grade
3/undifferentiated
2.79 1.63–4.76 b0.001 1.97 1.10–3.55 0.023
T-status: T2 (max.
diameter >2 cm)
3.89 1.78–8.54 0.001 3.12 1.19–8.17 0.020
Inﬁltration depth>5 mm 2.17 1.27–3.70 0.004 0.97 0.52–1.81 0.924
Vascular invasion positive 2.74 1.58–4.77 b0.001 1.94 1.07–3.50 0.028
Multifocality 1.10 0.59–2.05 0.772 a
Inguinofemoral metastasis 6.02 3.38–10.72 b0.001 5.30 2.81–10.01 b0.001
IDO expression 1.30 0.73–2.32 0.366 a
P16 positive 0.91 0.49–1.69 0.763 a
HLA-A downregulation 0.85 0.47–1.55 0.600 a
HLA-B/C downregulation 0.98 0.39–2.48 0.970 a
β2-m downregulation 0.92 0.13–6.68 0.935 a
CD8+ T-lymphocytes 1.00 1.00–1.00 0.726 a
Foxp3+ T-lymphocytes 1.00 1.00–1.01 0.301 a
CD8+/ Foxp3+ ratio 1.00 0.99–1.01 0.985 a
Bold values signify pb0.05.
a Not included in multivariate analysis.
192 R.A. de Jong et al. / Gynecologic Oncology 125 (2012) 186–193believe that our (negative) results in a large cohort of patients is of
major importance [13].
In summary, the current study investigated the presence and
prognostic impact of several immunological factors in vulvar carcino-
ma patients. The number of tumor-inﬁltrating CD8+ and Foxp3+
T-lymphocytes, HLA class I downregulation and IDO expression
were not related to survival in our population. The presence of ingui-
nofemoral metastasis was one of the “classical” prognostic character-
istics associated with poor survival and is of major importance in
determining prognosis and adequate treatment strategies in patients
with vulvar carcinoma. Although our results suggest that important
players in the adaptive immune system do not seem to have an inﬂu-
ence on survival, these results need to be conﬁrmed (or rejected) by fu-
ture research. Attempts have been made to identify tumor associated
antigens as possible targets in vulvar carcinoma [38]. Hopefully, this
will lead to more research concerning targeted therapy in an approach
to improve prognosis of vulvar carcinoma patients.Conﬂict of interest statement
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